Search

Your search keyword '"Cheville, John C"' showing total 1,043 results
Start Over Author "Cheville, John C" Publication Type Academic Journals
1,043 results on '"Cheville, John C"'

1. High-risk human papilloma virus status & outcomes for penile squamous cell carcinoma: A single institution experience

Author

Tekin, Burak, Cubilla, Antonio L., Cheville, John C., Smith, Carin Y., Jenkins, Sarah M., Dasari, Surendra, Enninga, Elizabeth Ann L., Norgan, Andrew P., Menon, Santosh, Whaley, Rumeal D., Hernandez, Loren Herrera, Jimenez, Rafael E., Garcia, Joaquin J., Thompson, R. Houston, Leibovich, Bradley C., Karnes, R. Jeffrey, Boorjian, Stephen A., Pagliaro, Lance C., Erickson, Lori A., Guo, Ruifeng, and Gupta, Sounak

Published
2024
Full Text
View/download PDF

2. Comparison of a modified staging system with 8th edition AJCC criteria in a North American cohort of pT2/pT3 HPV-negative penile squamous cell carcinoma

Author

Tekin, Burak, Sali, Akash P., Menon, Santosh, Cheville, John C., Smith, Carin Y., Jenkins, Sarah M., Dasari, Surendra, Enninga, Elizabeth Ann L., Norgan, Andrew P., Cubilla, Antonio L., Whaley, Rumeal D., Hernandez, Loren Herrera, Jimenez, Rafael E., Garcia, Joaquin J., Thompson, R. Houston, Leibovich, Bradley C., Karnes, R. Jeffrey, Boorjian, Stephen A., Pagliaro, Lance C., Erickson, Lori A., Guo, Ruifeng, and Gupta, Sounak

Published
2024
Full Text
View/download PDF

4. Molecular and Immunophenotypic Correlates of Metastatic Epithelioid Angiomyolipoma Include Alterations of TP53, RB1, and ATRX

Author

McCarthy, Michael R., Nichols, Paige E., Sharma, Vidit, Stanton, Melissa L., Reynolds, Jordan P., Pitel, Beth A., Halling, Kevin C., Lohse, Christine M., Herrera-Hernandez, Loren, Thompson, R. Houston, Leibovich, Bradley C., Jimenez, Rafael E., Boorjian, Stephen A., Cheville, John C., and Gupta, Sounak

Subjects
Gene mutations -- Health aspects, Tumor proteins -- Analysis, Immunohistochemistry -- Analysis, Metastasis -- Risk factors -- Prevention, Nephrectomy -- Patient outcomes, Health
Abstract

* Context.--Epithelioid angiomyolipomas (eAMLs) are rare tumors of the kidney that occur in patients with tuberous sclerosis complex or in a sporadic setting; a subset of these tumors exhibit metastatic behavior. Objective.--To analyze molecular profiling data to identify pathogenic alterations in rare cases of metastatic eAML, and to identify immunohistochemistry (IHC)-based surrogate markers. Design.--Molecular profiling data from the American Association for Cancer Research GENIE registry was accessed for 23 patients with angiomyolipomas, and 9 of 16 patients with eAMLs in our institutional registry were evaluated with next-generation sequencing. IHC was performed to screen for alterations of P53, RB, and ATRX for all 16 institutional cases. Results.--Combined alterations of 5 tumor-suppressor genes (TP53, ATRX, RB1, APC, and NF1) were identified using next-generation sequencing in 7 of 8 (88%) patients with metastatic disease compared to a single patient with nonmetastatic disease (RB1 variant of uncertain significance; 1 of 24, 4%). No cases with abnormal IHC results were identified in 11 patients with nonmetastatic disease compared to 3 of 5 patients with metastatic disease. Conclusions.--Our results show that the majority of metastatic eAMLs have mutations of 5 tumor-suppressor genes (TP53, ATRX, RB1, APC, and NF1), while these are rare in patients with nonmetastatic disease. Furthermore, IHC for P53, RB, and ATRX may serve as a screen for a subset of these alterations in resource-limited settings. These findings, if validated in larger data sets, have the potential to predict metastatic behavior in eAMLs. (Arch Pathol Lab Med. 2023;147:817-825; doi: 10.5858/ arpa.2022-0127-OA), Renal angiomyolipomas (AMLs) are mesenchymal neoplasms that are typically comprised of spindle cells arising from thick-walled vessels, intermixed with variable amounts of adipose tissue; they frequently express markers such as [...]

Published
2023

5. Single nucleotide polymorphism (SNP) chromosomal microarray as a diagnostic tool for mucinous tubular and spindle cell carcinoma: A validation study

Author

Nielson, Kaitlyn J., Rowsey, Ross, Dasari, Surendra, Sukov, William R., Kipp, Benjamin R., Raghunathan, Aditya, Whaley, Rumeal D., Ebare, Kingsley, Stanton, Melissa L., Reynolds, Jordan P., Sharma, Vidit, Thompson, R. Houston, Boorjian, Stephen A., Leibovich, Bradley C., Hernandez, Loren Herrera, Jimenez, Rafael E., Cheville, John C., and Gupta, Sounak

Published
2024
Full Text
View/download PDF

7. Prevalence, Predictors, and Oncologic Outcomes of Pelvic Organ Involvement in Women Undergoing Radical Cystectomy

Author

Avulova, Svetlana, Benidir, Tarik, Cheville, John C., Packiam, Vignesh T., Shah, Paras, Frank, Igor, Tollefson, Matthew K., Thompson, R. Houston, Karnes, R. Jeffrey, Thapa, Prabin, Kulkarni, Girish, and Boorjian, Stephen A.

Subjects
Women patients -- Statistics -- Care and treatment, Pelvic cancer -- Statistics -- Care and treatment -- Risk factors, Metastasis -- Statistics -- Care and treatment -- Risk factors, Bladder cancer -- Statistics -- Patient outcomes -- Care and treatment, Cystectomy -- Patient outcomes -- Statistics, Health
Abstract

* Context.--In women, radical cystectomy includes removal of the bladder, uterus, fallopian tubes, ovaries, and anterior vaginal wall, yet contiguous extension of urothelial carcinoma to all pelvic organs is rare and routine removal may be unnecessary. Objective.--To study pelvic organ involvement in women at radical cystectomy and investigate oncologic outcomes. Design.--Women with bladder cancer who underwent radical cystectomy at the Mayo Clinic and University of Toronto (1980-2018) were evaluated. Cancer-specific survival (CSS) was estimated with the Kaplan-Meier method; comparisons were made with the log-rank test. Associations with CSS were evaluated with Cox proportional hazard modeling. Results.--A total of 70 women with pT4a and 83 with pT3b cancer were studied. Organs involved were vagina (n = 41 of 70; 58.6%), uterus (n = 26 of 54; 48.1%), cervix (n = 15 of 54; 27.8%), fallopian tubes (n = 10 of 58; 17.2%), and ovaries (n = 7 of 58; 12.1%); 22 of 58 patients (37.9%) had >1 organ involved. Of 70 with pT4a cancer, 64 were available for survival analysis by 3 pelvic organ groups: vaginal only, vaginal and/or cervical/uterine, and vaginal and/or cervical/uterine and/or fallopian tubes/ovarian involvement. Three-year CSS for vaginal involvement only was 39%; it was 14% if cervical/uterine involvement, and Conclusions.--Isolated vaginal involvement should be separated from uterine and/or adnexal extension of urothelial carcinoma at pathologic staging. Direct ovarian extension is rare and routine removal may be unnecessary. doi: 10.5858/arpa.2021-0409-OA, In the United States, approximately 83 730 new bladder cancer cases are estimated to occur in 2021, accounting for 4.4% of all new cancer diagnoses (1 898 160). (1) Among [...]

Published
2023
Full Text
View/download PDF

8. Identification of amyloidosis of the urinary tract and prostate: Opportunities for early diagnosis & intervention in systemic disease

Author

Gilani, Sarwat I., Dasari, Surendra, Tekin, Burak, Hernandez, Loren Herrera, Cheville, John C., Jimenez, Rafael E., Rech, Karen L., Dao, Linda N., Howard, Matthew T., Dalland, Joanna C., Chiu, April, Theis, Jason D., Vrana, Julie A., Grogan, Martha, Thompson, R. Houston, Leibovich, Bradley C., Karnes, R. Jeffrey, Boorjian, Stephen A., Dispenzieri, Angela, McPhail, Ellen D., and Gupta, Sounak

Published
2023
Full Text
View/download PDF

9. Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma

Author

Tekin, Burak, Cheville, John C., Herrera Hernandez, Loren, Negron, Vivian, Smith, Carin Y., Jenkins, Sarah M., Dasari, Surendra, Enninga, Elizabeth Ann L., Norgan, Andrew P., Menon, Santosh, Cubilla, Antonio L., Whaley, Rumeal D., Jimenez, Rafael E., Thompson, R. Houston, Leibovich, Bradley C., Karnes, R. Jeffrey, Boorjian, Stephen A., Pagliaro, Lance C., Erickson, Lori A., Guo, Ruifeng, and Gupta, Sounak

Published
2023
Full Text
View/download PDF

10. Primary Female Urethral Carcinoma

Author

Aron, Manju, Park, Sanghui, Lowenthal, Brett M, Gupta, Sounak, Sahoo, Debashis, Cheville, John C, and Hansel, Donna E

Subjects
Rare Diseases, Cancer, Clinical Research, Urologic Diseases, Clinical Trials and Supportive Activities, Adult, Aged, Aged, 80 and over, Biopsy, Carcinoma, Female, Humans, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Predictive Value of Tests, Retrospective Studies, Sex Factors, Treatment Outcome, United States, Urethral Neoplasms, urethra, urethral carcinoma, urinary tract, staging, urothelial carcinoma, Clinical Sciences, Pathology
Abstract

Primary female urethral carcinoma is rare. Limited clinicopathologic information has hindered development of staging criteria in this disease. We analyzed 29 primary female urethral carcinoma resections from 3 academic medical centers to characterize histopathologic features, clinical outcomes, and applicability of current and a novel modified staging criteria. We complemented this analysis with review of fully embedded female autopsy urethras to detail anterior and posterior urethral wall histology. Primary female urethral carcinoma subtypes included urothelial carcinoma in situ (3/29, 10%), adenocarcinoma in situ (1/29; 3%), invasive urothelial carcinoma (13/29, 45%), clear cell carcinoma (5/29, 17%), adenocarcinoma not otherwise specified (4/29, 14%) and squamous cell carcinoma (3/29, 10%). Only 6/29 cases (21%) were originally assigned a stage at diagnosis. Using histologic landmarks specific to the female urethra, we modified existing eighth edition American Joint Committee on Cancer urethral staging to a histology-based female urethral carcinoma staging (UCS) system. UCS stages were defined as pTa/pTisUCS (noninvasive carcinoma), pT1UCS (subepithelial tissue invasion), pT2UCS (periurethral muscle invasion), pT3UCS (vaginal adventitia or surrounding fibrovascular tissue), and pT4UCS (anterior wall fibroadipose tissue or posterior vaginal wall). UCS staging was applicable to all cases and showed stepwise changes in disease recurrence with increasing stage and was statistically significant for disease-specific and overall survival in contrast to the American Joint Committee on Cancer staging system. This study of one of the largest cohort of primary female urethral carcinomas provides a modified histology-based staging system specific to female urethral anatomy that provides outcomes-related information, which may be further validated by larger multi-institutional studies.

Published
2020

17. Renin Production by Juxtaglomerular Cell Tumors and Clear Cell Renal Cell Carcinoma and the Role of Angiotensin Signaling Inhibitors

Author

Gupta, Sounak, Nichols, Paige, Lohse, Christine M., Kosari, Farhad, Kattah, Andrea G., Harris, Faye R., Karagouga, Giannoula, Mehra, Rohit, Fine, Samson W., Reuter, Victor E., Herrera-Hernandez, Loren, Zganjar, Andrew J., Britton, Cameron J., Potretzke, Aaron M., Boorjian, Stephen A., Thompson, R. Houston, Jimenez, Rafael E., Leibovich, Bradley C., Garovic, Vesna D., Cheville, John C., and Sharma, Vidit

Published
2022
Full Text
View/download PDF

20. Methylated DNA Markers in Voided Urine for the Identification of Clinically Significant Prostate Cancer.

Author

Shah, Paras, Taylor, William R., Negaard, Brianna J., Gochanour, Benjamin R., Mahoney, Douglas W., Then, Sara S., Devens, Mary E., Foote, Patrick H., Doering, Karen A., Burger, Kelli N., Nikolai, Brandon, Kaiser, Michael W., Allawi, Hatim T., Cheville, John C., Kisiel, John B., and Gettman, Matthew T.

Subjects
PROSTATE cancer patients, GENETIC markers, PROSTATE-specific antigen, PROSTATE biopsy, DNA methylation
Abstract

Introduction: Non-invasive assays are needed to better discriminate patients with prostate cancer (PCa) to avoid over-treatment of indolent disease. We analyzed 14 methylated DNA markers (MDMs) from urine samples of patients with biopsy-proven PCa relative to healthy controls and further studied discrimination of clinically significant PCa (csPCa) from healthy controls and Gleason 6 cancers. Methods: To evaluate the panel, urine from 24 healthy male volunteers with no clinical suspicion for PCa and 24 men with biopsy-confirmed disease across all Gleason scores was collected. Blinded to clinical status, DNA from the supernatant was analyzed for methylation signal within specific DNA sequences across 14 genes (HES5, ZNF655, ITPRIPL1, MAX.chr3.6187, SLCO3A1, CHST11, SERPINB9, WNT3A, KCNB2, GAS6, AKR1B1, MAX.chr3.8028, GRASP, ST6GALNAC2) by target enrichment long-probe quantitative-amplified signal assays. Results: Utilizing an overall specificity cut-off of 100% for discriminating normal controls from PCa cases across the MDM panel resulted in 71% sensitivity (95% CI: 49–87%) for PCa detection (4/7 Gleason 6, 8/12 Gleason 7, 5/5 Gleason 8+) and 76% (50–92%) for csPCa (Gleason ≥ 7). At 100% specificity for controls and Gleason 6 patients combined, MDM panel sensitivity was 59% (33–81%) for csPCa (5/12 Gleason 7, 5/5 Gleason 8+). Conclusions: MDMs assayed in urine offer high sensitivity and specificity for detection of clinically significant prostate cancer. Prospective evaluation is necessary to estimate discrimination of patients as first-line screening and as an adjunct to prostate-specific antigen (PSA) testing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

Author

Trpkov, Kiril, Hes, Ondrej, Williamson, Sean R., Adeniran, Adebowale J., Agaimy, Abbas, Alaghehbandan, Reza, Amin, Mahul B., Argani, Pedram, Chen, Ying-Bei, Cheng, Liang, Epstein, Jonathan I., Cheville, John C., Comperat, Eva, da Cunha, Isabela Werneck, Gordetsky, Jennifer B., Gupta, Sounak, He, Huiying, Hirsch, Michelle S., Humphrey, Peter A., Kapur, Payal, Kojima, Fumiyoshi, Lopez, Jose I., Maclean, Fiona, Magi-Galluzzi, Cristina, McKenney, Jesse K., Mehra, Rohit, Menon, Santosh, Netto, George J., Przybycin, Christopher G., Rao, Priya, Rao, Qiu, Reuter, Victor E., Saleeb, Rola M., Shah, Rajal B., Smith, Steven C., Tickoo, Satish, Tretiakova, Maria S., True, Lawrence, Verkarre, Virginie, Wobker, Sara E., Zhou, Ming, and Gill, Anthony J.

Published
2021
Full Text
View/download PDF

24. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

Author

Trpkov, Kiril, Williamson, Sean R., Gill, Anthony J., Adeniran, Adebowale J., Agaimy, Abbas, Alaghehbandan, Reza, Amin, Mahul B., Argani, Pedram, Chen, Ying-Bei, Cheng, Liang, Epstein, Jonathan I., Cheville, John C., Comperat, Eva, da Cunha, Isabela Werneck, Gordetsky, Jennifer B., Gupta, Sounak, He, Huiying, Hirsch, Michelle S., Humphrey, Peter A., Kapur, Payal, Kojima, Fumiyoshi, Lopez, Jose I., Maclean, Fiona, Magi-Galluzzi, Cristina, McKenney, Jesse K., Mehra, Rohit, Menon, Santosh, Netto, George J., Przybycin, Christopher G., Rao, Priya, Rao, Qiu, Reuter, Victor E., Saleeb, Rola M., Shah, Rajal B., Smith, Steven C., Tickoo, Satish, Tretiakova, Maria S., True, Lawrence, Verkarre, Virginie, Wobker, Sara E., Zhou, Ming, and Hes, Ondrej

Published
2021
Full Text
View/download PDF

27. Next generation sequencing-based identification of fusion-driven renal neoplasia: A single institution experience

Author

Tekin, Burak, Hofich, Christopher D., Pitel, Beth A., Schoolmeester, J. Kenneth, Whaley, Rumeal D., Raghunathan, Aditya, Ebare, Kingsley, Stanton, Melissa L., Reynolds, Jordan P., Sharma, Vidit, Thompson, R. Houston, Boorjian, Stephen A., Leibovich, Bradley C., Herrera Hernandez, Loren P., Jimenez, Rafael E., Cheville, John C., Ketterling, Rhett P., Geiersbach, Katherine B., Greipp, Patricia T., Sukov, William R., Kipp, Benjamin R., Halling, Kevin C., and Gupta, Sounak

Published
2024
Full Text
View/download PDF

29. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management

Author

Gupta, Sounak, Cheville, John C., Jungbluth, Achim A., Zhang, Yanming, Zhang, Lei, Chen, Ying-Bei, Tickoo, Satish K., Fine, Samson W., Gopalan, Anuradha, Al-Ahmadie, Hikmat A., Sirintrapun, Sahussapont J., Blum, Kyle A., Lohse, Christine M., Hakimi, A.Ari, Thompson, R.Houston, Leibovich, Bradley C., Berger, Michael F., Arcila, Maria E., Ross, Dara S., Ladanyi, Marc, Antonescu, Cristina R., and Reuter, Victor E.

Published
2019
Full Text
View/download PDF

33. Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma

Author

Mansfield, Aaron S., Peikert, Tobias, Smadbeck, James B., Udell, Julia B.M., Garcia-Rivera, Enrique, Elsbernd, Laura, Erskine, Courtney L., Van Keulen, Virginia P., Kosari, Farhad, Murphy, Stephen J., Ren, Hongzheng, Serla, Vishnu V., Schaefer Klein, Janet L., Karagouga, Giannoula, Harris, Faye R., Sosa, Carlos, Johnson, Sarah H., Nevala, Wendy, Markovic, Svetomir N., Bungum, Aaron O., Edell, Eric S., Dong, Haidong, Cheville, John C., Aubry, Marie Christine, Jen, Jin, and Vasmatzis, George

Published
2019
Full Text
View/download PDF

35. Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model.

Author

Pezeshki, Abdulmohammad, Cheville, John C., Florio, Angela B., Leibovich, Bradley C., and Vasmatzis, George

Subjects
IMMUNE checkpoint inhibitors, IMMUNE response, TUMOR-infiltrating immune cells, RENAL cancer, T cells
Abstract

Background: Only 20 percent of renal and bladder cancer patients will show a significant response to immune checkpoint inhibitor (ICI) therapy, and no test currently available accurately predicts ICI response. Methods: We developed an "immunotumoroid" cell model system that recapitulates the tumor, its microenvironment, and necessary immune system components in patient-derived spheroids to enable ex vivo assessment of tumor response to ICI therapy. Immunotumoroids were developed from surgically resected renal cell carcinomas and bladder carcinomas selected for high tumor-infiltrating lymphocytes (TILs) and survived more than a month without media exchange. Immunohistochemistry was used to detect immune and nonimmune cells in cryopreserved source tumors and the resulting immunotumoroids. Immunotumoroid response to ICIs (nivolumab, pembrolizumab, and durvalumab) and chemotherapy (cisplatin, gemcitabine, and paclitaxel) was monitored in real-time with Cytotox Red staining in an Incucyte device, and the immunotumoroid response was compared to retrospective clinical drug responses. Results: Six of the 13 cases tested grew viable immunotumoroid models, with failed cases attributed to extensive tumor tissue necrosis or excess lymphocytes preventing spheroid formation. One successfully cultured case was excluded from the study due to low TIL infiltration (<5%) in the primary tumor sample. The five remaining models contained immune cells (CD4+ and CD8+ T cells, and macrophages), non-immune cells (fibroblasts), and tumor cells. Chemotherapy and ICI drugs were tested in immunotumoroids from 5 cases and compared to clinical outcomes where data was available. Four/five models showed cell killing in response to chemotherapy and two/five showed sensitivity to ICI. In three cases, the immunotumoroid model accurately predicted the patient's clinical response or non-response to ICIs or chemotherapy. Conclusion: Our immunotumoroid model replicated the multicellular nature of the tumor microenvironment sufficiently for preclinical ICI screening. This model could enable valuable insights into the complex interactions between cancer cells, the immune system, and the microenvironment. This is a feasibility study on a small number of cases, and additional studies with larger case numbers are required including correlation with clinical response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Metastatic clear cell papillary renal cell 'tumour'.

Author

Gupta, Sounak, Dasari, Surendra, Sharma, Vidit, Atwell, Thomas D, Sivasankaran, Gopinath, Smoley, Stephanie A, Hardcastle, Jayson J, Lohse, Christine M, Tekin, Burak, Jimenez, Rafael E, Thompson, R Houston, Boorjian, Stephen A, Leibovich, Bradley C, and Cheville, John C

Subjects
TUMORS, METASTASIS, SINGLE nucleotide polymorphisms, RENAL cell carcinoma
Abstract

The article discusses the classification and characteristics of clear cell papillary renal cell tumours (CCPRCT). The recent World Health Organization (WHO) classification changed the nomenclature of these tumours to emphasize their indolent clinical behavior. The article presents a case study of a patient with a metastatic CCPRCT and compares the primary and metastatic tumors. The authors argue that the change in nomenclature may lead to unnecessary expensive testing and suggest reverting to the original terminology. They also highlight the need for further studies to determine the clinical impact of distinguishing CCPRCT from other renal cell carcinomas. [Extracted from the article]

Published
2024
Full Text
View/download PDF

41. Coffee consumption and risk of renal cell carcinoma

Author

Antwi, Samuel O., Eckel-Passow, Jeanette E., Diehl, Nancy D., Serie, Daniel J., Custer, Kaitlynn M., Arnold, Michelle L., Wu, Kevin J., Cheville, John C., Thiel, David D., Leibovich, Bradley C., and Parker, Alexander S.

Published
2017

43. Genomic analysis of spermatocytic tumors demonstrates recurrent molecular alterations in cases with malignant clinical behavior.

Author

Gupta, Sounak, Sholl, Lynette M, Yang, Yiying, Osunkoya, Adeboye O, Gordetsky, Jennifer B, Cornejo, Kristine M, Michalova, Kvetoslava, Maclean, Fiona, Dvindenko, Eugénia, Snuderl, Matija, Hirsch, Michelle S, Anderson, William J, Rowsey, Ross A, Jimenez, Rafael E, Cheville, John C, Sadow, Peter M, Colecchia, Maurizio, Ricci, Costantino, Ulbright, Thomas M, and Berney, Daniel M

Subjects
GENOMICS, OLDER men, TUMORS, DNA sequencing
Abstract

Spermatocytic tumor (ST) is a rare type of germ cell tumor that occurs exclusively in the postpubertal testis and typically affects elderly men. Most STs are benign, but rare cases exhibit aggressive clinical behavior, often in association with transition to sarcomatoid histology. Limited molecular analyses have been performed on STs; therefore, their genomic and epigenomic features remain incompletely described. Twenty‐seven samples from 25 individual patients were analyzed with a combination of DNA sequencing panels, genomic methylation profiling, SNP array, isochromosome (12p) [i(12p)] FISH, and immunohistochemistry. The series included five metastasizing tumors (three with sarcomatoid transformation, one anaplastic, and one conventional) and 20 non‐metastasizing tumors (14 anaplastic and six conventional). Anaplastic tumors comprised a monomorphic population of intermediate‐sized neoplastic cells, as previously described. Multiomic analyses demonstrated that there were two genomic subgroups of STs: one with diploid genomes and hotspot RAS/RAF variants and the other with global ploidy shift and absence of recurrent mutations. Relative gain of chromosome 9 was a consistent finding in both subgroups. A comparison of metastasizing and non‐metastasizing cases demonstrated that aggressive behavior was associated with the acquisition of pathogenic TP53 mutations and/or relative gains of 12p/i(12p). In cases with sarcomatoid transformation, TP53 mutations seem to underlie the transition to sarcomatoid histology. Genomic methylation analysis demonstrated that aggressive cases with gains of 12p cluster closer to pure seminomas than to STs without gains of 12p. In conclusion, STs include two genomic subgroups, characterized by global ploidy shifts without recurrent mutations and diploid genomes with RAS/RAF hotspot mutations, respectively. Biologic progression was associated with relative gains of 12p and TP53 mutations. The findings in STs with relative gains of 12p suggest that they may exhibit biologic characteristics akin to those seen in germ cell neoplasia in situ‐related germ cell tumors rather than non‐germ cell neoplasia in situ‐derived STs. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists

Author

Gandhi, Jatin S., Smith, Steven C., Paner, Gladell P., McKenney, Jesse K., Sekhri, Radhika, Osunkoya, Adeboye O., Baras, Alexander S., DeMarzo, Angelo M., Cheville, John C., Rafael, Jiminez E., Trpkov, Kiril, Colecchia, Maurizio, Ro, Jae Y., Montironi, Rodolfo, Menon, Santosh, Hes, Ondrej, Williamson, Sean R., Hirsch, Michelle S., Netto, George J., Fine, Samson W., Sirohi, Deepika, Kaushal, Seema, Sangoi, Ankur, Robinson, Brian D., Kweldam, Charlotte F., Humphrey, Peter A., Hansel, Donna E., Schultz, Luciana, Magi-Galluzzi, Cristina, Przybycin, Christopher G., Shah, Rajal B., Mehra, Rohit, Kunju, Lakshmi P., Aron, Manju, Kryvenko, Oleksandr N., Kench, James G., Kuroda, Naoto, Tavora, Fabio, van der Kwast, Theodorus, Grignon, David J., Epstein, Jonathan I., Reuter, Victor E., and Amin, Mahul B.

Published
2020
Full Text
View/download PDF

48. Correction to: Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia

Author

Trpkov, Kiril, Williamson, Sean R., Gill, Anthony J., Adeniran, Adebowale J., Agaimy, Abbas, Alaghehbandan, Reza, Amin, Mahul B., Argani, Pedram, Chen, Ying-Bei, Cheng, Liang, Epstein, Jonathan I., Cheville, John C., Comperat, Eva, da Cunha, Isabela Werneck, Gordetsky, Jennifer B., Gupta, Sounak, He, Huiying, Hirsch, Michelle S., Humphrey, Peter A., Kapur, Payal, Kojima, Fumiyoshi, Lopez, Jose I., Maclean, Fiona, Magi-Galluzzi, Cristina, McKenney, Jesse K., Mehra, Rohit, Menon, Santosh, Netto, George J., Przybycin, Christopher G., Rao, Priya, Rao, Qiu, Reuter, Victor E., Saleeb, Rola M., Shah, Rajal B., Smith, Steven C., Tickoo, Satish, Tretiakova, Maria S., True, Lawrence, Verkarre, Virginie, Wobker, Sara E., Zhou, Ming, and Hes, Ondrej

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results